A selective norepinephrine reuptake inhibitor for the treatment of narcolepsy and attention-deficit/hyperactivity disorder (ADHD). Available from
by Drugs.com. This medicine contains 18.6 mg of atomoxetine. Atomoxetine is used to treat patients with attention-deficit hyperactivity disorder (ADHD) as well as narcolepsy. Atomoxetine belongs to a group of medicines called selective norepinephrine reuptake inhibitors (SNRIs). These medicines work by allowing norepinephrine to be reabsorbed back into the brain. This allows norepinephrine to be available in higher concentrations and therefore helps in improving attention, focus, and hyperactivity symptoms.
This medicine should not be used in children.
ADHD can cause excessive sleepiness, excessive sweating, tremors, muscle cramps, blurred vision, difficulty concentrating, or changes in bowel habits. You should not use atomoxetine during pregnancy, unless recommended by your doctor.
Some common side effects of atomoxetine include:
If you experience any of the side effects, stop using atomoxetine and contact your doctor right away.
You should swallow the capsule whole with water. You should not crush, break, or chew it. You should take a deep breath before or after taking atomoxetine. Do not take more than one atomoxetine tablet in 24 hours.
Take your medicine at regular intervals (up to 6 hours).
Like all medicines, atomoxetine can cause side effects. If you have any of the following serious side effects, stop using this medicine and contact your doctor:
Contact your doctor or seek emergency medical attention if your symptoms get worse or do not improve after 4-6 hours.
The most common side effects of atomoxetine include:
Contact your doctor or seek emergency medical attention if your symptoms get worse or do not improve after 6 hours.
Common side effects of atomoxetine include:
These side effects are usually temporary and will resolve once the medicine is stopped. Contact your doctor or seek immediate medical help if you experience any serious side effects.
The information provided in this article is not a substitute for professional medical advice or treatment. You should not rely upon the content provided in this article for specific medical advice. If you have any questions or concerns, please talk to your doctor.
If you have any questions or concerns about your medicines, ask your doctor or pharmacist.Copyright © 2025 The Korean Academy of Sleep Medicine.
See.The content provided in this article is a summary of a complete list of possible side effects. It does not cover all possible side effects. It does not replace the consultation and care provided by a qualified clinician. It also does not imply any prescription or over-the-counter (OTC) prescribing from your doctor or pharmacist.A licensed clinician (BMC) can provide this content by using additional information such as medical questions or instruction sheets. This information does not identify you. It does not cover all possible uses.
If you have questions about this information, ask your doctor or pharmacist. You can also contact The MC at info@mcs.
To use Strattera, find out which tablet is included with which you are given an email. If you give a specific drug the drug itself is included in. For your treatment, the usual starting dose is 80-90 mg. The dosage should be reduced to 30-40 mg. For a patient, a single 30-40 mg dose is usually given. The patient will then be instructed on how to give this dose. Strattera is not sold in a patient-controlled. You will be given a chance to ask for a lower dose to see if this helps. You should not give this dose to the same patient twice because the chance of side effects will make it difficult to give the same dose to both patients. To give the same dose, you can give two doses, once for the same condition, and once for a different use. There are a number of ways to give a single dose of Strattera. In some patients, the usual dose of the medication is 30-40 mg. In others, the usual dose is the maximum tolerated. This means the patient will be given two doses at once. It also means that you will be given the medication at the same time every day to treat the same condition. It also means that you will be given the medication every day to help the medication be better in the body for the day. For this reason, you should always give this dose on a lighter or lighter day. To give a single dose, take this medication with a glass of water. The medication should be swallowed whole with plenty of water. The amount of medication that can be taken is based on the amount of the dose. For example, if a patient takes 60 mg Strattera, and has a doctor’s recommendation of 80 mg Strattera, and gets an 80 mg dose of the medication, he will take 80 mg Strattera. The usual dose of Strattera is 30-40 mg, although the maximum is 80 mg daily. The dose can be reduced to 30-40 mg if the patient has been advised otherwise. To give a single dose of Strattera, take this medication 30-40 mg. To give a single dose, take this medication 30-40 mg.
Dear Dr. Schatzky:I’m a 30-year-old male who recently stopped using methylphenidate for an eating disorder. I started taking stimulants during the manic phase of my life, and I still get the urge to binge- eating when I feel like I’m doing something wrong. I have noticed that I tend to binge eat more often. My thoughts are racing, but I’m not tempted to do so. I’m also not eating a good diet, and I don’t feel hungry as much. I am in the middle of a cycle of eating a large meal at a restaurant, and I’m eating dinner in a restaurant for the first time. In addition to being a binge eater, I also have a lot of physical activity. I’m not in a social setting, but I don’t do much exercise.
I’m a 45-year-old male who was diagnosed with Attention Deficit Hyperactivity Disorder (ADHD). My doctor prescribed stimulants to help me focus. I began taking Strattera at the age of 40. The first three weeks, I noticed that I didn’t binge eat much, but that I was still eating a lot, so I stopped taking it. I was also not able to eat well, and I started eating more frequently than usual. I’m now feeling really anxious. The next four weeks are a lot of eating. I’m eating three times a day.
I’m a 30-year-old male who was diagnosed with ADHD. I started taking Strattera at the age of 40. The first three weeks, I noticed that I don’t eat very much, but that I was still eating a lot, so I stopped taking it. I was also eating a lot of food. It made me anxious. The next four weeks were a lot of eating. I’m feeling really anxious, and I’m still eating very well. I’ve also noticed that I don’t eat much. The last few weeks, I’m having trouble eating. I’m also in the middle of a cycle of eating a large meal at a restaurant. I’m eating dinner in a restaurant for the first time, and I’m eating dinner in a restaurant for the first time. I’m eating dinner in a restaurant for the first time. I am also not eating a good diet, and I don’t eat a good diet. I am in the middle of a cycle of eating a large meal at a restaurant. I have no energy. I can’t sleep, I can’t do anything else. I am having problems with sleep, and I don’t sleep.
I’m not an obsessive reader of the books I’m reading about ADHD. I don’t like to talk to people. I’m not comfortable with the idea of people asking me about ADHD. I’m also not comfortable with the idea of people asking me about ADHD. I don’t like being judged. I have no other interests, and I don’t like being judged by people. I’m not comfortable with the idea that I should be judged by people, and I’m not comfortable with the idea of people asking me about ADHD.
I’m having trouble sleeping. I don’t want to sleep. I’m also not comfortable with being judged by people, but I like being judged by people. I don’t like being judged by people. I’m having trouble eating, and I’m having problems with eating. I’m in the middle of a cycle of eating a large meal at a restaurant.
My doctor prescribed Strattera at the age of 40.
Eli Lilly has signed a record-setting deal to acquire the ADHD medication Strattera, and the company will also sell its first generic form of the medication.
Strattera, which has an annual sales of more than $3 billion worldwide, is Lilly’s first generic version of the stimulant medication.
“Strattera is the first to gain significant traction in the ADHD market,” said Lilly chairman and chief executive officer Daniel J. Lechleiter. “This acquisition provides our shareholders with the opportunity to invest in developing innovative medicines that benefit the ADHD market.”
Strattera’s launch marked the beginning of a new era in pharmaceutical sales and distribution for the company.
While the launch of Strattera was a key development, Lilly has yet to achieve sales growth for the medication until today.
The agreement, signed last month, also includes a $250 million bonus for Lilly, which would be used for its current product, Strattera. It will also be paid to Lilly for future sales.
Lilly shares fell 1.4 percent in afternoon trading at $41.32 on the New York Stock Exchange.
The deal provides Lilly the exclusive right to use Strattera’s generic version as a stand-alone medication and to sell the generic version at a price that is less than those paid by the company.
“Strattera is the first to gain significant traction in the ADHD market, and this agreement marks the beginning of a new era in pharmaceutical sales and distribution,” said Lechleiter.
Lilly shares dropped 9.4 percent in afternoon trading at $50.77 on the New York Stock Exchange.
A Lilly spokesperson said the company’s decision to make the generic version available for sale in the United States reflects its commitment to a high-quality, high-value pharmaceutical market. In addition to Strattera’s market share, Lilly has also been working on a new indication for the medication, a second indication of a new indication for ADHD in children.
Lilly’s shares are down 2.4 percent to $18.17 on the New York Stock Exchange. The stock is trading at a low close.
Lilly shares are up 2.4 percent to $18.17 on the New York Stock Exchange.
Teva Pharmaceutical Industries LP, a unit of Teva Pharmaceutical Industries, is acquiring the rights to the drug, and Teva’s patent expires, and its U. S. patent expires. Lilly is the exclusive licensee of the rights to the drug from Teva.
Lilly shares are down 2.4 percent to $23.45 on the New York Stock Exchange.
View moreLilly’s stock price fell 2.4 percent to $13.00 in afternoon trading. The company said the loss is due to the loss of sales of Strattera in the U. and related products and services that have been sold by Lilly in the U.
The company said it would continue to make payments to patients to improve the patient experience, as well as expand the reach of Lilly’s product offerings, including Strattera.
Lilly shares have fallen 0.9 percent to $22.04 on the New York Stock Exchange.
Lilly shares are down 3.6 percent to $21.58 on the New York Stock Exchange.
Lilly shares are down 6.3 percent to $23.33 on the New York Stock Exchange.
Lilly shares are down 6.3 percent to $24.03 on the New York Stock Exchange.
Lilly is the first to gain significant traction in the ADHD market, and this agreement provides Lilly the opportunity to invest in developing innovative medicines that benefit the ADHD market. The agreement will help Lilly gain market share in the first of its three main product categories, including Strattera.
The company also will sell its first generic version of the medication, which was approved by the U. Food and Drug Administration (FDA) in March 2017. Strattera was approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).
Lilly shares are up 2.5 percent to $22.04 on the New York Stock Exchange.
patent expires, and the company is the exclusive licensee of the rights to the drug from Teva.
Salt Composition in both
Salt Composition
Atomoxetine 60mg(same for both)
You Searched
Strip of 15 tablets
We only sell the best substitute from top brands
Our Recommendation
Thermus Fertomid (Atomoxetine 60mg) 15 Tablet 10s
1,824+ Customers trust this
WHO GMP Certified
Marketed by
Doctor ApprovedMedicine Comparison
PlatinumRx is dedicated to delivering dependable and trustworthy information to empower our customers. However, the information presented here is solely for general informational purposes and should not be utilized for diagnosing, preventing, or treating health issues. It is not intended to establish a doctor-patient relationship or serve as a substitute for professional medical advice.
Pantosec DSR 30/40mg PR Capsule 10sPantosec 40mg Tablet 10sCipvildin M 500/50mg Tablet 15sAb Rozu 10mg Tablet 10sCipcal D3 60000IU Capsule 4sCipcal 500mg/250IU Tablet 15sDapaquest 10mg Tablet 10sMontecip LC 5/10mg Tablet 10sLipvas 10mg Tablet 10sParacip 650mg Tablet 10sView More
Aerolife inhalation Device 1sAir Space Wit Exhle Valve Device 1sBp Monitor (Omron) Hem 8712 Device 1sContour Plus System 1sDigital Thermometer Mercury Device 1sDuohaler DPI Device 1sIbreathe DPI Inhealer Device 1sMachaler DPI Device 1sMacspacer Device 1sNovopen 4 | Diabetes Monitoring Devices 1s
Each of these are independently-except their warnings.Aerolife Inhalation
50aratnamrd (ustainablysave) (aldesecretina) (atomoxetine) (drospirenone and ethynetonethesione)
Stade de France Pharmacy